| Literature DB >> 29216864 |
Ni Zeng1, Chun Wan1, Jiangyu Qin1, Yanqiu Wu1, Ting Yang1, Yongchun Shen2, Fuqiang Wen1, Lei Chen3.
Abstract
BACKGROUND: The ability of interleukins (ILs) to differentiate tuberculous pleural effusion from other types of effusion is controversial. The aim of our study was to summarize the evidence for its use of ruling out or in tuberculous pleural effusion.Entities:
Keywords: Diagnosis; Interleukin; Meta-analysis; Tuberculous pleural effusion
Mesh:
Substances:
Year: 2017 PMID: 29216864 PMCID: PMC5721598 DOI: 10.1186/s12890-017-0530-3
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Clinical summary of all studies
| Interleukins | Author | Country(incidence) | Year | Cut-off (pg/ml) | Index test | Design |
|---|---|---|---|---|---|---|
| IL-27 | Wu et al. [ | China (high) | 2013 | 900.8 | ELISA | P |
| Liu et al. [ | China (high) | 2015 | 1012 | ELISA | R | |
| Luo et al. [ | China (high) | 2015 | 353.47 | ELISA | R | |
| Skouras et al. [ | Greece (low) | 2015 | 391 | ELISA | NA | |
| Sun et al. [ | China (high) | 2014 | 838 | ELISA | R | |
| Valdes et al. [ | Spain (low) | 2014 | 550 | ELISA | P | |
| Yang et al. [ | China (high) | 2012 | 1007 | ELISA | P | |
| Niu et al. [ | China (high) | 2012 | 846 | ELISA | R | |
| IL-18 | Chen et al. [ | China (high) | 2011 | 843.7 | ELISA | R |
| Dai et al. [ | China (high) | 2015 | 503.58 | ELISA | R | |
| Ding et al. [ | China (high) | 2008 | 640 | ELISA | R | |
| Hu et al. [ | China (high) | 2009 | 365 | ELISA | R | |
| Jiang et al. [ | China (high) | 2009 | 503.88 | ELISA | R | |
| Klimiuk et al. [ | Poland (low) | 2014 | 327.7 | ELISA | P | |
| Liu et al. [ | China (high) | 2015 | 438.86 | ELISA | R | |
| Okamoto et al. [ | Japan (low) | 2005 | 992.7 | ELISA | NA | |
| Wang et al. [ | China (high) | 2008 | 358 | ELISA | R | |
| Wu et al. [ | China (high) | 2006 | 150 | ELISA | R | |
| Xiong et al. [ | China (high) | 2007 | 358 | ELISA | R | |
| Yu et al. [ | China (high) | 2003 | 150 | ELISA | NA | |
| IL-6 | Kiropoulos et al. [ | Greece (low) | 2007 | 17,215 | ELISA | P |
| Wang et al. [ | China (high) | 2005 | 1950 | ELISA | R | |
| Wong et al. [ | China (high) | 2003 | 4000 | ELISA | P | |
| Wu et al. [ | China (high) | 2005 | 550 | ELISA | R | |
| Zan et al. [ | China (high) | 2014 | 277 | RIA | NA | |
| Yang et al. [ | China (high) | 2006 | 220 | RIA | R | |
| IL-33 | Lee et al. [ | Korea (low) | 2013 | 10 | ELISA | R |
| Li et al. [ | China (high) | 2015 | 68.3 | ELISA | R | |
| Liu et al. [ | China (high) | 2015 | 19.31 | ELISA | R | |
| Xuan et al. [ | China (high) | 2014 | 19.86 | ELISA | R | |
| IL-12 | Chen et al. [ | China (high) | 2011 | 785.6 | ELISA | R |
| Gu et al. [ | China (high) | 2002 | 300 | ELISA | NA | |
| Jiang et al. [ | China (high) | 2010 | 87.41 | ELISA | R | |
| Okamoto et al. [ | Japan (low) | 2005 | 129 | ELISA | NA | |
| Tian et al. [ | China (high) | 2004 | 73.5 | ELISA | R | |
| Zhou et al. [ | China (high) | 2012 | 90 | ELISA | R | |
| IL-2 | Liu et al. [ | China (high) | 2015 | 67.17 | ELISA | R |
| Liu et al. [ | China (high) | 2015 | 99.08 | ELISA | R | |
| Ren et al. [ | China (high) | 2014 | 41.91 | ELISA | R | |
| Wu et al. [ | China (high) | 2005 | 250 | ELISA | R | |
| Zhang et al. [ | China (high) | 1998 | 400 | RIA | R | |
| IL-12p40 | Fernández et al. [ | Venezuela (low) | 2011 | 89 | ELISA | NA |
| Klimiuk et al. [ | Poland (low) | 2014 | 296 | ELISA | P | |
| Tural Önür et al. [ | Turkey (low) | 2015 | 210 | ELISA | NA | |
| Valdes et al. [ | Spain (low) | 2009 | 550 | ELISA | P | |
| IL-8 | Yamada et al. [ | Japan (low) | 2001 | 228 | ELISA | R |
| Yang et al. [ | China (high) | 2001 | 1000 | ELISA | R | |
| IL-10 | Wu et al. [ | China (high) | 2005 | 50 | ELISA | R |
| IL-22 | Jin et al. [ | China (high) | 2011 | 49 | ELISA | R |
| Yuan et al. [ | China (high) | 2014 | 186.6 | ELISA | R | |
| IL-23 | Klimiuk et al. [ | Poland (low) | 2014 | 0.7 | ELISA | P |
| IL-31 | Gao et al. [ | China (high) | 2015 | 67.5 | ELISA | R |
Abbreviations: IL interleukin, ELISA enzyme-linked immunosorbent assay, RIA radioimmunoassay, NA not available, P prospective, R retrospective
Fig. 1Flow diagram of study selection. QUADAS: Quality Assessment of Diagnostic Accuracy Studies
Diagnostic performance of interleukins from individual studies
| Interleukins | Author | Subjects | TP | FP | FN | TN |
|---|---|---|---|---|---|---|
| IL-27 | Wu et al. [ | 81 | 38 | 1 | 2 | 40 |
| Liu et al. [ | 147 | 88 | 3 | 7 | 49 | |
| Luo et al. [ | 62 | 32 | 1 | 2 | 27 | |
| Skouras et al. [ | 121 | 8 | 10 | 2 | 101 | |
| Sun et al. [ | 76 | 38 | 1 | 2 | 35 | |
| Valdes et al. [ | 431 | 64 | 54 | 6 | 307 | |
| Yang et al. [ | 174 | 63 | 1 | 5 | 105 | |
| Niu et al. [ | 44 | 23 | 1 | 0 | 20 | |
| IL-18 | Chen et al. [ | 64 | 28 | 4 | 6 | 26 |
| Dai et al. [ | 52 | 21 | 2 | 2 | 27 | |
| Ding et al. [ | 72 | 33 | 2 | 1 | 36 | |
| Hu et al. [ | 102 | 48 | 3 | 4 | 47 | |
| Jiang et al. [ | 60 | 26 | 2 | 4 | 28 | |
| Klimiuk et al. [ | 203 | 27 | 20 | 17 | 139 | |
| Liu et al. [ | 80 | 36 | 3 | 4 | 37 | |
| Okamoto et al. [ | 43 | 4 | 1 | 7 | 31 | |
| Wang et al. [ | 44 | 17 | 2 | 2 | 23 | |
| Wu et al. [ | 48 | 20 | 2 | 4 | 22 | |
| Xiong et al. [ | 86 | 41 | 3 | 5 | 37 | |
| Yu et al. [ | 52 | 30 | 0 | 2 | 20 | |
| IL-6 | Kiropoulos et al. [ | 97 | 22 | 17 | 3 | 55 |
| Wang et al. [ | 71 | 33 | 2 | 1 | 35 | |
| Wong et al. [ | 66 | 29 | 8 | 3 | 26 | |
| Wu et al. [ | 109 | 31 | 9 | 25 | 44 | |
| Zan et al. [ | 56 | 30 | 5 | 12 | 9 | |
| Yang et al. [ | 54 | 20 | 2 | 2 | 30 | |
| IL-33 | Lee et al. [ | 220 | 47 | 56 | 13 | 104 |
| Li et al. [ | 87 | 27 | 16 | 5 | 39 | |
| Liu et al. [ | 147 | 82 | 5 | 13 | 47 | |
| Xuan et al. [ | 44 | 20 | 2 | 3 | 19 | |
| IL-12 | Chen et al. [ | 64 | 30 | 5 | 4 | 25 |
| Gu et al. [ | 52 | 27 | 5 | 5 | 25 | |
| Jiang et al. [ | 60 | 22 | 3 | 8 | 27 | |
| Okamoto et al. [ | 43 | 6 | 1 | 5 | 31 | |
| Tian et al. [ | 190 | 120 | 17 | 21 | 32 | |
| Zhou et al. [ | 73 | 31 | 8 | 14 | 20 | |
| IL-2 | Liu et al. [ | 80 | 25 | 6 | 15 | 34 |
| Liu et al. [ | 147 | 53 | 18 | 42 | 34 | |
| Ren et al. [ | 88 | 39 | 4 | 3 | 42 | |
| Wu et al. [ | 109 | 34 | 21 | 22 | 32 | |
| Zhang et al. [ | 69 | 23 | 6 | 4 | 36 | |
| IL-12p40 | Fernández et al. [ | 60 | 11 | 20 | 9 | 20 |
| Klimiuk et al. [ | 203 | 38 | 44 | 6 | 115 | |
| Tural Önür et al. [ | 120 | 42 | 27 | 10 | 41 | |
| Valdes et al. [ | 96 | 36 | 17 | 3 | 40 | |
| IL-8 | Yamada et al. [ | 70 | 17 | 14 | 4 | 35 |
| Yang et al. [ | 64 | 38 | 4 | 2 | 20 | |
| IL-10 | Wu et al. [ | 109 | 46 | 7 | 20 | 36 |
| IL-22 | Jin et al. [ | 56 | 23 | 1 | 5 | 27 |
| Yuan et al. [ | 87 | 47 | 7 | 5 | 28 | |
| IL-23 | Klimiuk et al. [ | 203 | 13 | 66 | 31 | 93 |
| IL-31 | Gao et al. [ | 71 | 33 | 0 | 7 | 31 |
Abbreviations: IL interleukin, TP true-positive, FP false-positive, FN false-negative, TN true-negative
Statistical measures of heterogeneity, cut-off effect, and publication bias for each interleukin
| interleukins | I2 for heterogeneity in InDOR(%) | Spearman’s coefficient | Egger test | Deeks test |
|---|---|---|---|---|
| IL-27 | 53.5 | −0.467 | 0.101 | 0.57 |
| IL-18 | 61.7 | −0.511 | 0.5 | 0.73 |
| IL-6 | 77.8 | −0.657 | 0.532 | 0.66 |
| IL-33 | 77.7 | −1.00 | 0.359 | 0.54 |
| IL-12 | 34.3 | 0.493 | 0.029 | 0.23 |
| IL-2 | 88.4 | −0.900 | 0.17 | 0.18 |
| IL-12p40 | 83.2 | −0.800 | 0.9 | 0.34 |
Fig. 2Forest plot of the sensitivities and specificities. a. interleukin-27, b. interleukin-18. The calculated pooled mean with corresponding confidence interval is also reported
Pooled means of sensitivity and specificity, diagnostic odds ratio(DOR), area under the curve(AUC), and calculated likelihood ratios for each interleukin
| Interleukins | sensitivity(95%CI) | specificity(95%CI) | DOR | AUC | PLR | NLR |
|---|---|---|---|---|---|---|
| IL-27 | 0.93(0.90–0.95) | 0.95(0.90–0.98) | 264 | 0.95 | 19.5(9.4–40.5) | 0.07(0.05–0.11) |
| IL-18 | 0.87(0.79–0.92) | 0.92 (0.88–0.95) | 76 | 0.95 | 10.8 (7.2–16.3) | 0.14(0.09–0.23) |
| IL-6 | 0.86(0.70–0.94) | 0.84(0.74–0.90) | 30 | 0.90 | 5.2(3.0–9.1) | 0.17(0.07–0.41) |
| IL-33 | 0.84(0.77–0.89) | 0.80(0.65–0.89) | 20 | 0.88 | 4.2(2.21–7.9) | 0.20(0.13–0.32) |
| IL-12 | 0.78(0.69–0.84) | 0.83(0.72–0.91) | 17 | 0.86 | 4.6(2.8–7.8) | 0.27(0.20–0.37) |
| IL-2 | 0.67(0.61–0.73) | 0.76(0.70–0.82) | 11 | 0.86 | 3.4(1.7–6.8) | 0.36(0.20–0.66) |
| IL-12p40 | 0.82(0.66–0.91) | 0.65(0.54–0.74) | 8 | 0.76 | 2.3(1.6–3.4) | 0.28(0.13–0.61) |
Abbreviations: IL interleukin, DOR diagnostic odds ratio, AUC area under the curve, PLR positive likelihood ratio, NLR negative likelihood ratio
Fig. 3Summary receiver operating characteristic (SROC) curve for all the interleukins included
Fig. 4Summary of QUADAS-2 assessments of included studies. QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies-2. Patient Selection: Describe methods of patient selection; Index Text: Describe the index test and how it was conducted and interpreted; Reference Standard: Describe the reference standard and how it was conducted and interpreted; Flow and Timing: Describe any patients who did not receive the index tests or reference standard or who were excluded from the 2 × 2 table, and describe the interval and any interventions between index tests and the reference standard